Corient Capital Partners’s Exact Sciences EXAS Stock Holding History

Corient Capital Partners’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,509	Closed	-$239K	–	726
2021 Q3	$239K	Buy	2,509 +493	+24%	+$52.1K	0.02%	575
2021 Q2	$251K	Sell	2,016 -104	-5%	-$12.4K	0.02%	544
2021 Q1	$279K	Buy	2,120 +323	+18%	+$44.2K	0.02%	464
2020 Q4	$238K	Buy	+1,797	New	+$217K	0.02%	436
2020 Q1	–	Sell	-4,442	Closed	-$411K	–	436
2019 Q4	$411K	Buy	4,442 +88	+2%	+$7.74K	0.05%	308
2019 Q3	$393K	Buy	4,354 +1,985	+84%	+$226K	0.06%	300
2019 Q2	$280K	Buy	+2,369	New	+$239K	0.04%	312

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Corient Capital Partners's EXAS Position: Q4 2021 in Review

Corient Capital Partners sold out of Exact Sciences (EXAS) in Q4 2021, closing a stake of 2,509 shares — an estimated $239K sold.

Corient Capital Partners first reported a position in EXAS in Q2 2019 and held it in 7 quarters. The position peaked at $411K in Q4 2019. 596 funds tracked by Wall St. Rank hold EXAS as of Q4 2021.

Corient Capital Partners reported no remaining Exact Sciences position as of Q4 2021 after selling out during the quarter.
Corient Capital Partners sold 2,509 Exact Sciences shares in Q4 2021, an estimated $239K.
Corient Capital Partners first reported a position in Exact Sciences in Q2 2019 and held it in 7 quarters.
Corient Capital Partners's Exact Sciences position peaked at $411K in Q4 2019.
596 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2021.

Based on Corient Capital Partners's 13F filing for Q4 2021, filed 11 Feb 2022.